Hereditary Cancer Panel
£525.00
Skip to product information
Hereditary Cancer Panel
Reviewed and Approved by
Registered Professionals
£525.00
Informed Genomics - Comprehensive Hereditary Cancer Panel
Our hereditary cancer clinical service at Informed Genomics aims to identify individuals at a higher-than-population risk for hereditary cancer. We offer a range of hereditary cancer panels to study genes associated with the most common hereditary cancers ranging from a comprehensive multi-cancer panel to targeted panels for breast, ovarian, colorectal, prostate, melanoma and pancreatic cancer.
The panels have been expertly curated using current literature and national testing guidelines to maximise clinical actionability, whilst minimising uncertainty. Our routine turnaround time for this testing is 3-4 weeks, however, prioritisation options are available. Please contact us to discuss your requirements.
The final clinical report summarises test results by providing variant interpretation, the implications of the results, and any recommended actions. Full genetic counselling is available for patients to explain test results and the associated implications, and to inform relevant support networks.
Standard Turnaround time: 14days (and 2 days transport via post)
Priority Turnaround time: 10days (and 1 day transport via DHL)
Biomarkers checked
| Comprehensive Hereditary Cancer Panel | APC, ATM1, BAP1, BARD1, BMPR1A, BRCA1, BRCA2, BRIP1, CDH1, CDK4, CDKN2A, CHEK22, EPCAM3, HOXB13, MLH1, MSH2, MSH6, MUTYH, NF1, NTHL1, PALB2, PMS24, POLD1, POLE, PTEN, RAD51C, RAD51D, SMAD4, STK11, TP53, VHL |
| Hereditary Breast Cancer Panel | ATM1, BARD1, BRCA1, BRCA2, CHEK22, PALB2, PTEN, RAD51C, RAD51D, STK11, TP53 |
| Hereditary Breast and Gynaecological Cancer Panel | ATM1, BARD1, BRCA1, BRCA2, BRIP1, CHEK22, EPCAM3, MLH1, MSH2, MSH6, PALB2, PTEN, RAD51C, RAD51D, STK11, TP53 |
| Hereditary Prostate Cancer | ATM1, BRCA1, BRCA2, CHEK22, EPCAM3, HOXB13, MLH1, MSH2, MSH6 |
| Hereditary Colorectal Cancer (including Lynch syndrome) Panel | APC, BMPR1A, EPCAM3, MLH1, MSH2, MSH6, MUTYH, NTHL1, PMS24, POLD1, POLE, PTEN, SMAD4, STK11, TP53 |
| Hereditary Melanoma Cancer Panel | BAP1, BRCA2, CDK4, CDKN2A, PTEN |
| Hereditary Pancreatic Cancer Panel | APC, BRCA1, BRCA2, CDKN2A EPCAM3, MLH1, MSH2, MSH6, PALB2, STK11, TP53, VHL |
Collection Method
- Saliva Sample
Saliva extraction has been set up as a less invasive sample collection method, allowing easy sample collection within the health centre or self-sampling at home.
The sampling tubes provide long-term stabilisation of the saliva at room temperature, ensuring that any delays in transit do not impact on the quality of the DNA extracted.
Our sampling kits contain:
-1x clam shell pack containing a sample collection tube with funnel and lid, plus sample collection instructions issued by the tube manufacturer
-1x consent form
-1x leakproof sample mailing pouch
-2x tamper seals
-1x tube label
-1x prepaid postage returns box
Eating, drinking, smoking, or chewing gum should be avoided for 30 minutes prior to sampling as this may affect the quality of the sample and invalidate the test.
When is hereditary cancer testing used?
Hereditary cancer is defined as cancer that has been caused by an inherited genetic variant. Inheriting certain genetic variants does not necessarily mean that cancer will develop, but the lifetime risk is significantly increased, and it is estimated that 5-10% of all cancer cases have a genetic variant that leads to cancer susceptibility.
A genetic cause is suspected when the clinical features or family history include the following, in which case a hereditary cancer panel is recommended:
-early age of onset
-multiple primary tumours
-multifocal tumour sites
-bilateral tumour appearance in paired organs
-the same type of tumour in first or second-degree relatives or same tumour type clustering within a family
-rare tumour types
-rare tumours associated with birth defects
It is important to note that not all genetic variants that lead to an increased susceptibility to cancer are associated with a family history. At Informed Genomics, they offer Hereditary Cancer Panel to anyone over 18 years of age who is believed to be at risk of developing cancer, regardless of personal or familial cancer history.
This test is considered a screening test, not a diagnostic test. Before making any treatment decisions, all patients should discuss their results with their healthcare provider, who can recommend confirmatory, diagnostic testing where appropriate.
Accreditations
Informed Genomics manufactures and processes IGL Hereditary Cancer Panels and offers an efficient and effective, quality-driven service which ensures the high performance of our hereditary cancer testing service. This is underpinned by a strong and robust Quality Management System accredited to UKAS ISO 15189:2012
Informed Genomics Hereditary screening is distributed in the UK by Biox Medical
Return and refund policy
We accept Order Hereditary Cancer Panel packages back for a full refund if it is returned within 14 days in an unused/undamaged condition. We cannot accept packages that has been damaged or used.
The kit must be used within 3 months otherwise stability and quality of the kit cannot be guaranteed and therefore void and cannot be refunded.
for more information please contact info@officialchriskirt.com